ObjectiveGI, the integrated research and technology services platform company, announced its 10th “Center of Research Excellence.” ObjectiveGI is a physician-partnered model that integrates gastroenterology (GI) research services into local practices, providing clinical research as a management option for specialists in support of patient care and practice enhancement. With this 10th center, the company is now partnering with more than 100 GI physicians across the country.
“It’s an exciting time to be in healthcare and support science at the point of care,” says Colleen Hoke, president and CEO, ObjectiveGI. “By partnering with leading GI physicians to create cutting-edge programs, we’re working together to provide the necessary data aimed at developing new NASH therapies and, ultimately, improving patient outcomes.”
Since launching the first “Center of Research Excellence” in 2018, ObjectiveGI and its partners have supported value-based care initiatives for more than 3,000 patients. Today, these centers can be found on-site at GI practices located in Alabama, Arkansas, Florida, Maryland, Michigan, North Carolina, South Carolina and Tennessee. Looking forward, ObjectiveGI plans to double the number of “Center of Excellence” sites by the end of 2020, expanding its transformative presence while driving meaningful partnerships and improved patient outcomes.
“We will continue to add value for all stakeholders and advance emerging care solutions for patients through each one of our research partnerships,” says Dr. Don Lazas, chief medical officer, ObjectiveGI. “Aligning incentives for research sponsors and payers, while providing a premier research infrastructure that allows for GI providers to conduct pivotal clinical trials within the workflow of their practices, remains at the forefront of the work with our physician partners.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.